Piper Jaffray analyst JP McKim say he's sticking with shares of Inogen after the company reported Q2 results below expectations and lowered full-year guidance. The stock is trading below the med-tech average valuation and management adamantly committed to double-digit growth in 2020, McKim tells investors in a research note titled "Another Tough Quarter Though We Are Not Throwing In The Towel." If investors believe the company can grow double-digits, then today is a buying opportunity, says the analyst. He reiterates an Overweight rating on Inogen while noting his $140 price target is under review. The stock in midday trading is down 22%, or $12.04, to $43.14.